RMD vs UNH

ResMed Inc. (RMD) continues to demonstrate robust performance as a global leader in sleep apnea and respiratory care. Its Q3 FY2026 results showed healthy 10.8% YoY revenue growth, EPS beat ($2.86 vs $2.79 consensus), and gross margin expansion to 62.8%. These are strong indicators of a well-managed, profitable company in an established healthcare sector. However, this analysis specifically target...

UnitedHealth Group (UNH) remains a robust, high-quality mega-cap in the mature and highly regulated healthcare sector. Q1 2026 adjusted EPS of $7.23, a recent dividend increase to $2.32, and some analyst upgrades (e.g., Truist to $440, Goldman Sachs Conviction Buy) reflect solid operational performance and financial strength. However, these are characteristics of a stable compounder, not a company...